Intravenous administration of xenogenic adipose-derived mesenchymal stem cells (ADMSC) and ADMSC-derived exosomes markedly reduced brain infarct volume and preserved neurological function in rat after acute ischemic stroke

Chen, Kuan‐Hung; Chen, Chih‐Hung; Wallace, Christopher Glenn; Yuen, Chun-Man; Kao, Gour-Shenq; Chen, Yi‐Ling; Shao, Pei‐Lin; Chen, Yung‐Lung; Chai, Han‐Tan; Lin, Kun‐Chen; Liu, Chu-Feng; Chang, Hsueh‐Wen; Lee, Mel S.; Yip, Hon‐Kan

doi:10.18632/oncotarget.12902

Cited by 181 publications

(225 citation statements)

References 39 publications

(97 reference statements)

Supporting

Mentioning

197

Contrasting

Unclassified

Order By: Relevance

“…A more recent rat study examined the effects of MSCs combined with MSC‐EVs , demonstrating that combined MSC and MSC‐EV delivery was superior in terms of brain protection and neurological recovery when compared with MSC transplantation or EV injection only. These studies raised the question of how therapeutic effects of EVs may be boosted by loading naïve EVs with biologically active molecules such as noncoding RNAs, which by means of EVs may safely be transported to target tissues .…”

Section: Preclinical Studies Using Evs In Animal Models Associated Wimentioning

confidence: 99%

“…To the best of the authors' knowledge, six different studies have examined effects of EVs in ischemic stroke models, most in rats and one in mice [112][113][114][116][117][118]. In the first rat study, Chopp and colleagues [113] intravenously applied MSC-EVs in a model of transient intraluminal middle cerebral artery occlusion.…”

Section: Preclinical Studies Using Evs In Animal Models Associated Wimentioning

confidence: 99%

“…A more recent rat study examined the effects of MSCs combined with MSC-EVs [114], demonstrating that combined MSC This list is not intended to be complete. It reflects a selection of studies based on their influences on the development of this field.…”

Section: Preclinical Studies Using Evs In Animal Models Associated Wimentioning

confidence: 99%

See 2 more Smart Citations

Concise Review: Extracellular Vesicles Overcoming Limitations of Cell Therapies in Ischemic Stroke

Doeppner

Bähr

Hermann

et al. 2017

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Despite recent advances in stroke therapy, current therapeutic concepts are still limited. Thus, additional therapeutic strategies are in order. In this sense, the transplantation of stem cells has appeared to be an attractive adjuvant tool to help boost the endogenous regenerative capacities of the brain. Although transplantation of stem cells is known to induce beneficial outcome in (preclinical) stroke research, grafted cells do not replace lost tissue directly. Rather, these transplanted cells like neural progenitor cells or mesenchymal stem cells act in an indirect manner, among which the secretion of extracellular vesicles (EVs) appears to be one key factor. Indeed, the application of EVs in preclinical stroke studies suggests a therapeutic role, which appears to be noninferior in comparison to the transplantation of stem cells themselves. In this short review, we highlight some of the recent advances in the field of EVs as a therapeutic means to counter stroke. STEM CELLS TRANSLATIONAL MEDICINE 2017;6:2044-2052 SIGNIFICANCE STATEMENTDespite recent success in therapeutic approaches against stroke, especially in the field of endovascular therapy, additional therapeutic means are still in order. In this sense, the application of extracellular vesicles might be an interesting tool to induce post-ischemic neuroregeneration, overcoming the limitations and risks of stem cell transplantation themselves.

show abstract

Section: Preclinical Studies Using Evs In Animal Models Associated Wimentioning

confidence: 99%

Section: Preclinical Studies Using Evs In Animal Models Associated Wimentioning

confidence: 99%

See 1 more Smart Citation

Concise Review: Extracellular Vesicles Overcoming Limitations of Cell Therapies in Ischemic Stroke

Doeppner

Bähr

Hermann

et al. 2017

Stem Cells Translational Medicine

View full text Add to dashboard Cite

show abstract

“…In preclinical studies, ASC administered through intravenous and intracarotid injection have shown the potential to reduce disability and improve motor function up to 56 days after ischemic stroke (Fig. A) . ASC also reduced the size of the infarct, reduced acute brain swelling, improved in myelination, increased vascular supply, reduced scar formation, and decreased chronic atrophy (Fig.…”

Section: Resultsmentioning

confidence: 99%

Concise Review: Using Fat to Fight Disease: A Systematic Review of Nonhomologous Adipose-Derived Stromal/Stem Cell Therapies

et al. 2018

View full text Add to dashboard Cite

The objective of this Review is to describe the safety and efficacy of adipose stem/stromal cells (ASC) and stromal vascular fraction (SVF) in treating common diseases and the next steps in research that must occur prior to clinical use. Pubmed, Ovid Medline, Embase, Web of Science, and the Cochrane Library were searched for articles about use of SVF or ASC for disease therapy published between 2012 and 2017. One meta-analysis, 2 randomized controlled trials, and 16 case series were included, representing 844 human patients. Sixty-nine studies were performed in preclinical models of disease. ASCs improved symptoms, fistula healing, remission, and recurrence rates in severe cases of inflammatory bowel disease. In osteoarthritis, ASC and SVF improved symptom-related, functional, radiographic, and histological scores. ASC and SVF were also shown to improve clinical outcomes in ischemic stroke, multiple sclerosis, myocardial ischemia, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, chronic liver failure, glioblastoma, acute kidney injury, and chronic skin wounds. These effects were primarily paracrine in nature and mediated through reduction of inflammation and promotion of tissue repair. In the majority of human studies, autologous ASC and SVF from liposuction procedures were used, minimizing the risk to recipients. Very few serious, treatment-related adverse events were reported. The main adverse event was postprocedural pain. SVF and ASC are promising therapies for a variety of human diseases, particularly for patients with severe cases refractory to current medical treatments. Further randomized controlled trials must be performed to elaborate potential safety and efficacy prior to clinical use. Stem Cells 2018;36:1311-1328.

show abstract

“…Administration of cell-free exosomes derived from MSCs is sufficient to exert therapeutic effects of intact MSCs after brain injury [176,231,232,234]. The exosomes transfer RNAs and proteins to other cells which then act epigenetically to alter the function of the recipient cells [175,178,205,215,225].…”

Section: Extracellular Vesicles and Exosomesmentioning

confidence: 99%

Traumatic Penumbra: Opportunities for Neuroprotective and Neurorestorative Processes

Regner¹,

Meirelles²,

Simon³

2018

Traumatic Brain Injury - Pathobiology, Advanced Diagnostics and Acute Management

View full text Add to dashboard Cite

Traumatic brain injury (TBI) is a major cause of morbidity and mortality worldwide. Understanding the pathophysiology of TBI is crucial for the development of more effective therapeutic strategies. At the moment of the traumatic impact, transfer of kinetic forces causes neurologic damage; this primary injury triggers a secondary wave of biochemical cascades, together with metabolic and cellular changes, called secondary neural injury. These areas of ongoing secondary injury, or areas of "traumatic penumbra," represent crucial targets for therapeutic interventions. This chapter is focused on the interplay between progression of parenchymal injury and the neuroprotective and neurorestorative processes that are emerging and developing subsequently to traumatic impact. Thus, we emphasized the role of traumatic penumbra in TBI pathogenesis and suggested a crucial contribution of the neurovascular units (NVUs) and paracrine effects of exosomes and miRNAs in promoting neurological recovery.

show abstract

Intravenous administration of xenogenic adipose-derived mesenchymal stem cells (ADMSC) and ADMSC-derived exosomes markedly reduced brain infarct volume and preserved neurological function in rat after acute ischemic stroke

Cited by 181 publications

References 39 publications

Concise Review: Extracellular Vesicles Overcoming Limitations of Cell Therapies in Ischemic Stroke

Concise Review: Extracellular Vesicles Overcoming Limitations of Cell Therapies in Ischemic Stroke

Concise Review: Using Fat to Fight Disease: A Systematic Review of Nonhomologous Adipose-Derived Stromal/Stem Cell Therapies

Traumatic Penumbra: Opportunities for Neuroprotective and Neurorestorative Processes

Contact Info

Product

Resources

About